research use only

MRT-2359 GSPT1 Degrader

Name: MRT-2359
Brand: Selleck Chemicals
SKU: E1427
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1427

MRT-2359 is a potent degrader of GSPT1. It exhibits anti-tumor activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.

MRT-2359 E3 Ligase chemical Chemical Structure

Quality Control

Batch: E142701 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.01%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.01

Related Targets	Proteasome E1 Activating DUB SUMO p97 E2 conjugating
Other E3 Ligase Inhibitors	Iberdomide (CC-220) Skp2 inhibitor C1 (SKPin C1) Apcin Avadomide (CC-122) PRT4165 VL285 SZL P1-41 CC-90009 VH298 Mezigdomide (CC-92480)

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (201.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	495.38	Formula	C₂₂H₁₇F₄N₃O₆	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2803881-11-8	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	GSPT1
References	[1] https://pubmed.ncbi.nlm.nih.gov/37457123/ [2] https://aacrjournals.org/cancerres/article/82/12_Supplement/3929/703293

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07745361	RECRUITING	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer; Prostate Cancer (Adenocarcinoma)	Monte Rosa Therapeutics, Inc	2026-08	PHASE2
NCT05546268	ACTIVE_NOT_RECRUITING	NSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC With High or Low L-MYC or N-MYC Expression; HR-positive, HER2-negative Breast Cancer; Prostate Cancer	Monte Rosa Therapeutics, Inc	2022-10-12	PHASE1; PHASE2
NCT05546268	Recruiting	NSCLC\|SCLC\|High Grade Neuroendocrine Cancer\|DLBCL\|L-MYC and N-MYC Amplified Solid Tumors\|NSCLC With High or Low L-MYC or N-MYC Expression\|HR-positive HER2-negative Breast Cancer\|Prostate Cancer	Monte Rosa Therapeutics Inc	2022-10-12	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):